Baxalta, Inc. (BXLT)

Oncology Corporate Profile

HQ Location

One Baxter Parkway
Deerfield, IL 60015

Company Description

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
pacritinibJAK2/FLT3 dual inhibitorMyelofibrosisIII
imalumab / BAX 069MIF inhibitorColorectal cancerII
Oncaspar_ / pegaspargaseAcute Myelogenous Leukemia (AML)II

View additional information on product candidates here »


Recent News Headlines

16 companies we lost in 2016

12/20/2016 07:00 pm

5 Biggest Acquisitions of 2016

12/16/2016 06:00 pm

Baxter Going Strong

8/30/2016 08:00 pm

[$$] Shire lifts guidance as Baxalta spurs strong sales growth

8/2/2016 02:02 pm

[at Financial Times] - Shire, the acquisitive London-listed pharmaceuticals group that specialises in drugs for rare diseases, has reported strong growth across the business and lifted its guidance for the year. The drugmaker ...